33837-83-1

Upstream product

• 100-97-0 hexamethylenetetramine 
• 57373-95-2 2-tert-butyl-6-methoxy phenol 
• 33877-17-7 2-tert-Butyl-6-methoxy-4-((E)-propenyl)-phenol 
• 2505-15-9 6-(tert-butyl)-2-methoxy-4-methylphenol 
• 93-51-6 2-Methoxy-4-methylphenol 
• 121-33-5 vanillin 
• 75-65-0 tert-butyl alcohol 
• 33837-82-0 4-allyl-2-tert-butyl-6-methoxyphenol 
• 33837-81-9 2-Methoxy-6-tert.-butyphenylallylaether 

Downstream Products

• 33837-86-4 2-tert-Butyl-4-hydroxymethyl-6-methoxy-phenol 
• 33837-88-6 C₂₄H₃₄O₄ 
• 580-72-3 (2RS,3RS)-2,3-bis-(4-hydroxy-3-methoxybenzyl)butyrolactone 
• 3688-23-1 2,3-Bis(3-methoxy-4-hydroxybenzyl)butane-1,4-diol 
• 131068-32-1 2-tert-Butyl-6-methoxy-4-[(E)-2-(5-methyl-isothiazol-3-yl)-vinyl]-phenol 
• 131068-27-4 2-tert-Butyl-6-methoxy-4-[(E)-2-(3-methyl-isoxazol-5-yl)-vinyl]-phenol 
• 33837-87-5 2-tert-Butyl-4-ethoxymethyl-6-methoxy-phenol 
• 1263820-40-1 C₃₃H₃₄O₄ 
• 321696-38-2 3-tert-butyl-4,5-bis(methoxymethoxy)benzaldehyde 

Relevant academic research and scientific papers

ALPHAvBETA1 INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.

Novel antioxidant and preparation method thereof

The invention relates to a novel antioxidant and a preparation method thereof. The structural formula of the antioxidant is shown in img file = 'dest _ path _ image 001. TIF 'wi = '152 'he = '86 ', wherein R is an alkyl group CnH2n +1, and n is 0 to 22. A

Encapsulation and release mechanisms in coordination polymer nanoparticles

The interplay of guest encapsulation and release mechanisms in nanoscale metal-organic vehicles and its effect on the drug-delivery kinetics of these materials were investigated through a new multidisciplinary approach. Two rationally-designed molecular g

Self-assembly of alkylcatechols on HOPG investigated by scanning tunneling microscopy and molecular dynamics simulations

Two alkylcatechols have been studied by means of STM at the liquid-solid interface. While for catechol 3 no molecular domains on the surface have been observed most likely due to the steric constraints imposed by the tert-butyl group, catechol 2 self-orga

An efficient method for the synthesis of lignans

An efficient approach for the synthesis of several types of lignans (dibenzylbutanediols, dibenzylbutanes, substituted tetrahydrofurans, aryldihydronaphthalenes, arylnaphthalenes, and aryltetralins) was developed. The regioselective oxidative coupling of ethyl ferulate was used as the key step.

Regioselective oxidative coupling approach to the synthesis of (±)-matairesinol and (±)-secoisolariciresinol

An efficient method for the synthesis of (±)-matairesinol and (±)-secoisolariciresinol is presented. By using 5-(tert-butyl)ferulic acid as a precursor, a regioselective oxidative coupling step was realized, which gave the desired coupling product in much higher yield (91%) than the literature value (ca. 20%). Georg Thieme Verlag Stuttgart.

Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors

A series of styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles were prepared and found to be dual inhibitors of 5-lipoxygenase and cyclooxygenase in rat basophilic leukemia cells. Compounds from this series also were found to inhibit the in vivo production of LTB4 when dosed orally in rats. Among these compounds, di-tert-butylphenols 19 and 33 exhibit oral activity in various models of inflammation and, most importantly, are devoid of ulcerogenic potential.